
Budding Bioengineer Shares Impressions Of 2015 BIO Exhibit Floor
What follows is the 2015 BIO International Conference as viewed through the eyes of a student and first time attendee — a fresh perspective of the tradeshow floor at BIO that we industry veterans might often take for granted.
Continue Reading..

Did You Miss Some Opportunities At BIO This Year?
The tagline on the cover of the BIO International Convention’s 2015 pre-event planner is “Forge SUPER powerful connections.” If you think this an exaggeration, then you are obviously not trying hard enough.
Continue Reading..

Does Adversity Build Character Or Reveal It?
Denice Torres is the president of McNeil Consumer Healthcare, a Johnson & Johnson company, and winner of HBA’s 2015 WOTY award. Listening to her acceptance speech reminded me of legendary pro football coach Vince Lombardi’s philosophy — “Adversity doesn’t build character, it reveals it.”
Continue Reading..

What Biopharma Trends Should Pharma Execs Be Paying Attention To?
Peter Young, a 35-year biopharmaceutical industry veteran, presented at the 2015 BIO International, and his valuable session includes some key industry trends biopharmaceutical executives should be paying a close attention to.
Continue Reading..

What Areas Are Often Overlooked By Academics Turned Biotech Entrepreneurs?
Peter Young, a 35-year biopharmaceutical industry veteran has seen his share of missteps by academics aspiring to become entrepreneurs and has some advice on partnering with VCs.
Continue Reading..

Are You Ready For A Grant-funding QA Audit?
Peter Young, a 35-year pharma industry veteran and executive-in-residence with AM Pappas & Associates, shares exclusive insights (that aren’t part of his presentation at BIO International) on how to prepare for a QA grant-funding audit — all from a lesson learned the hard way.
Continue Reading..

What Is the Role VCs Play In Partnering With Small Biotech?
When Peter Young began planning his session proposal for this year’s BIO International Conference, he wanted to create a session worthy of your time. His session may be fascinating, but the young, a 35-year veteran of the biopharmaceutical industry, took some time to provide additional industry insights — ones you are not likely to gather by only attending his session.
Continue Reading..

J&J's Solution To The Compassionate-Use Hot Potato
While I applaud the leadership of J&J for coming up with what seems to be a fair, equitable, and ethical solution to the phenomenon of desperate patients using social media to campaign for early access to medication, to me it feels more like a version of compassionate-use hot potato to tackle a problem nobody really wants to be associated with.
Continue Reading..

One's Perception Is One's Reality
A quote from Albert Einstein saying, “We cannot solve our problems with the same thinking we used when we created them.” When you consider that HBA was founded over 35 years ago, I wonder if its present mission of advancing the impact of women in healthcare worldwide is being supported by a name that is not inclusive of all its present day stakeholders.
Continue Reading..

Isn't It Time We Just Combine Biotech and Pharma Under One Category?
Considering all the biotech and pharma M&A activity, isn’t it about time we just combine the two and start referring to it as one — the biopharmaceutical industry? After all, that is the end result of all this M&A.
Continue Reading..
This website uses cookies to ensure you get the best experience on our website. Learn more